Advocacy News

The changes include an updated scoring methodology which could improve scores for many ophthalmologists starting with the 2024 performance year/2026 payment year.

CMS signaled a willingness to review the request in its Nov. 12 meeting with the Academy and the American Society of Retina Specialists.

Practices can note access issues in precertification requests to be granted an exemption from step therapy requirements. 

Rep. Mariannette Miller-Meeks, MD, R-Iowa, Rep. Kim Shrier, MD, D-Wash., and other OPHTHPAC-supported candidates have been reelected as control of the House of Representatives waits to be decided.

Academy members William Clifford, MD, of Kansas, and Steven Magie, MD, of Arkansas, won their campaigns for state office.

The final rule could affect about 3,500 hospitals and 6,100 ambulatory surgical centers (ASC). Here are the key takeaways.

The bill would eliminate the nearly 3% cut proposed for 2025 and provide a one-year inflationary update. Urge your representatives to co-sponsor this critical legislation today.

The Academy urged large commercial insurers and Medicare Advantage plans to suspend anti-VEGF step therapy requirements in response to Pine Pharmaceuticals discontinuation of repackaged Avastin (bevacizumab).

MIPS participants who are randomly selected for the audit will receive email notifications between October 2024 and April 2025.

The Academy is engaging with alternative suppliers and pushing CMS to intervene on Medicare Advantage plan step therapy requirements for Avastin.